Takeda HR chief sells shares to cover tax on awards

Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling 6,774 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS.

Rhea-AI Filing Summary

Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling 6,774 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. After this sale, she directly holds 53,029 ADS.

Insider Trade Summary

Net Seller: 6,774 shares

Net Sell 1 txn

Insider Greenway Nicola Deidre Petal

Role Chief Human Resources Officer

Sold 6,774 shs ($116K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2, F3	6,774	$17.10	$116K

Holdings After Transaction: American Depositary Shares — 53,029 shares (Direct)

Footnotes (3)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. The total in Column 5 represents the amount of American Depositary Shares held by the Reporting Person as of the date of this filing.

Key Figures

Shares sold: 6,774 American Depositary Shares Weighted average sale price: $17.10 per ADS Shares held after transaction: 53,029 American Depositary Shares +2 more

5 metrics

Shares sold 6,774 American Depositary Shares Mandatory sale on 2026-08-10 to cover taxes on vesting equity awards

Weighted average sale price $17.10 per ADS Price for the 6,774 ADS sold on 2026-08-10

Shares held after transaction 53,029 American Depositary Shares Direct holdings of the reporting person as of the filing date

Transaction type Sale in open market or private transaction SEC transaction code S for non-derivative American Depositary Shares

Net buy/sell shares -6,774 shares transactionSummary netBuySellShares indicating a net-sell transaction

Key Terms

American Depositary Shares, mandatory sale to cover taxes, vesting of equity awards, weighted average price

4 terms

American Depositary Shares financial

"The total in Column 5 represents the amount of American Depositary Shares held"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

vesting of equity awards financial

"taxes associated with the vesting of equity awards held by the Reporting Person"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Takeda (TAK) executive Nicola Greenway sell in this Form 4 filing?

Nicola Deidre Petal Greenway sold 6,774 American Depositary Shares of Takeda Pharmaceutical on 2026-08-10 at a weighted average price of $17.10 per ADS, according to the Form 4 insider transaction report.

Why were Takeda (TAK) shares sold by Nicola Greenway in this transaction?

The filing states the sale represents a mandatory sale to cover taxes associated with the vesting of equity awards held by Nicola Greenway, indicating the sale was made specifically to satisfy related tax obligations.

How many Takeda (TAK) ADS does Nicola Greenway hold after this Form 4 sale?

After the reported sale, Nicola Deidre Petal Greenway holds 53,029 American Depositary Shares of Takeda Pharmaceutical directly, as of the date of the filing, reflecting her remaining equity position following the tax-related transaction.

What was the sale price in Nicola Greenway’s Takeda (TAK) Form 4 transaction?

The reported price is a weighted average of $17.10 per ADS. A footnote explains that detailed information on the number of shares sold at each separate price within the relevant ranges is available upon request from specified parties.

Was Nicola Greenway’s Takeda (TAK) sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as a trading-plan transaction, and the footnotes describe the sale as a mandatory tax-cover sale related to equity award vesting, without referencing any pre-arranged trading plan.

What role does Nicola Greenway hold at Takeda (TAK) in this Form 4?

Nicola Deidre Petal Greenway is identified as Chief Human Resources Officer of Takeda Pharmaceutical, and the reported Form 4 transaction reflects her personal, direct ownership of American Depositary Shares in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 09:29 PM Accepted by SEC EDGAR 08/12/2026 - 09:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenway Nicola Deidre Petal

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		6,774	D	$17.1(2)	53,029(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The total in Column 5 represents the amount of American Depositary Shares held by the Reporting Person as of the date of this filing.

	/s/ Samuel Ntonme, by power of attorney, for Nicola D. Greenway	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)